Case-control study of endogenous steroid hormones and endometrial cancer

Journal of the National Cancer Institute

Volumn 88, Issue 16, 1996, Pages 1127-1135

  Potischman, Nancy ^a,i   Hoover, Robert N ^a   Brinton, Louise A ^a   Siiteri, Pentti ^a   Dorgan, Joanne F ^a   Swanson, Christine A ^a   Berman, Michael L ^b   Mortel, Rodrigue ^c   Twiggs, Leo B ^d   Barrett, Rolland J ^e   Wilbanks, George D ^f   Persky, Victoria ^g   Lurain, John R ^h  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f RUSH MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^h NORTHWESTERN UNIVERSITY   (United States)

ⁱ NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GESTAGEN; SEX HORMONE BINDING GLOBULIN;

ADULT; AGED; ARTICLE; BODY FAT; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOMETRIUM CANCER; FEMALE; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; NONHUMAN; OBESITY; POSTMENOPAUSE; PREMENOPAUSE; STEROID BLOOD LEVEL;

EID: 9444280099     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.16.1127     Document Type: Article

References (49)

1. Herrinton LJ, Weiss NS. Postmenopausal unopposed estrogens. Characteristics of use in relation to risk of endometrial carcinoma. Ann Epidemiol 1993;3:308-18.
2. Weiss NS, Sayvetz TA. Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med 1980;302:551-4.
3. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, van Belle G. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 1991;338:274-7.
4. Brinton LA, Hoover RN. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. The Endometrial Cancer Collaborative Group. Obstet Gynecol 1993;81:265-71.
5. Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA 1987;257:796-800.
6. Dahlgren E, Friberg LG, Johansson S, Lindstrom B, Oden A, Samsioe G, et al. Endometrial carcinoma; ovarian dysfunction - a risk factor in young women. Eur J Obstet Gynecol Reprod Biol 1991;41:143-50.
7. Stanford JL. Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, et al. Oral contraceptives and endometrial cancer: do other risk factors modify the association? Int J Cancer 1993;54:243-8.
8. Voigt LF, Deng Q, Weiss NS. Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA). Cancer Causes Control 1994;5:227-33.
9. Siiteri PK. Steroid hormones and endometrial cancer. Cancer Res 1978;38(11 Pt 2):4360-6.
10. Henderson BE, Ross RK, Pike MC, Casagrande JT. Endogenous hormones as major factor in human cancer. Cancer Res 1982;42:3232-9.
11. Siiteri PK, Nisker JA, Hammond GL. Hormonal basis of risk factors for breast and endometrial cancer. In: Iacobelli S, King RJ, Lindner HR, Lippman ME, editors. Hormones and cancer. New York: Raven Press, 1980.
12. Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 1992; 167:1317-25.
13. Ron E, Lunenfeld B, Menczer J, Blumstein T, Katz L, Oelsner G, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1987; 125:780-90.
14. Key TJ, Pike MC. The dose-effect relationship between "unopposed" oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988;57:205-12.
15. Parazzini F, La Vecchia C, Bocciolone L, Franceschi S. The epidemiology of endometrial cancer. Gynecol Oncol 1991;41:1-16.
16. MacDonald PC, Siiteri PK. The relationship between the extraglandular production of estrone and the occurence of endometrial neoplasia. Gynecol Oncol 1974;2:259-63.
17. MacDonald PC, Edman CD, Hemsell DL, Porter JC, Siiteri PK. Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 1978;130:448-55.
18. Siiteri PK. Adipose tissue as a source of hormones. Am J Clin Nutr 1987;45(1 Suppl):277-82.
19. Nisker JA, Hammond GL, Davidson BJ, Frumar AM, Takaki NK, Judd HL, et al. Serum sex hormone-binding globulin capacity and the percentage of free estradiol in postmenopausal women with and without endometrial carcinoma. A new biochemical basis for the association between obesity and endometrial carcinoma. Am J Obstet Gynecol 1980;138:637-42.
20. Nyholm HC, Nielsen AL, Lyndrup J, Dreisler A, Hugen C, Haug E. Plasma oestrogens in postmenopausal women with endometrial cancer. Br J Obstet Gynecol 1993;100:1115-9.
21. Pettersson B, Bergstrom R, Johansson ED. Serum estrogens and androgens in women with endometrial cancer. Gynecol Oncol 1986;25:223-33.
22. Swanson CA, Potischman N, Wilbanks GD, Twiggs LB, Mortel R, Berman ML, et al. Relation of endometrial cancer risk to past and contemporary body size and fat distribution. Cancer Epidemiol Biomarkers Prev 1993;2:321-7.
23. Elliott EA, Matanoski GM, Rosenshein NB, Grumbine FC, Diamond EL. Body fat patterning in women with endometrial cancer. Gynecol Oncol 1990;39:253-8.
24. Kirschner MA, Samojlik E, Drejka M, Szmal E, Schneider G, Ertel N. Androgen-estrogen metabolism in women with upper body versus lower body obesity. J Clin Endocrinol Metab 1990;70:473-9.
25. Austin H, Austin JM Jr, Partridge EE, Hatch KD, Shingleton HM. Endometrial cancer, obesity, and body fat distribution. Cancer Res 1991; 51:568-72.
26. Schapira DV, Kumar NB, Lyman GH, Cavanagh D, Roberts WS. LaPolla J. Upper-body fat distribution and endometrial cancer risk. JAMA 1991; 266:1808-11.
27. Kaye SA, Folsom AR, Soler JT, Prineas RJ, Potter JD. Associations of body mass and fat distribution with sex hormone concentrations in postmenopausal women. Int J Epidemiol 1991;20:151-6.
28. Sherman BM, Korenman SG. Measurement of serum LH, FSH, estradiol and progesterone in disorders of the human menstrual cycle: the inadequate luteal phase. J Clin Endocrinol Metab 1974;39:145-9.
29. Benjamin F, Deutsch S. Plasma levels of fractionated estrogens and pituitary hormones in endometrial carcinoma. Am J Obstet Gynecol 1976; 126:638-47.
30. Judd HL, Lucas WE, Yen SS. Serum 17β-estradiol and estrone levels in postmenopausal women with and without endometrial carcinoma. J Clin Endocrinol Metab 1976;43:272-8.
31. Calanog A, Sall S, Gordon GG, Southren AL. Androstenedione metabolism in patients with endometrial cancer. Am J Obstet Gynecol 1977;129: 553-6.
32. Judd HL, Davidson BJ, Frumar AM, Shamonki IM, Lagasse LD, Ballon SC. Serum androgens and estrogens in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 1980;136:859-71.
33. Davidson BJ, Gambone JC, Lagasse LD, Castaldo TW, Hammond GL, Sitteri PK, et al. Free estradiol in postmenopausal women with and without endometrial cancer. J Clin Endocrinol Metab 1981;52:404-8.
34. Schenker JG, Weinstein D, Okon E. Estradiol and testosterone levels in the peripheral and ovarian circulations in patients with endometrial cancer. Cancer 1979;44:1809-12.
35. Abraham GE, Odell WD, Swerdloff RS, Hopper K. Simultaneous radioimmunoassay of plasma FSH, LH, progesterone, 17-hydroxyprogesterone, and estradiol-17 beta during the menstrual cycle. J Clin Endocrinol Metab 1972;34:312-8.
36. Cassidenti DL, Vijod AG, Vijod MA, Stanczyk FZ, Lobo RA. Short-term effects of smoking on the pharmacokinetic profiles of micronized estradiol in postmenopausal women. Am J Obstet Gynecol 1990;163(6 Pt 1):1953-60.
37. Vermeulen A, Stoica T, Verdonck L. The apparent free testosterone concentration, an index of androgenicity. J Clin Endocrinol Metab 1971;33: 759-67.
38. Rosner W. A simplified method for the quantitative determination of testosterone-estradiol-binding globulin activity in human plasma. J Clin Endocrinol Metab 1972;34:983-8.
39. Potischman N, Falk RT, Laiming VA, Siiteri PK, Hoover RN. Reproducibility of laboratory assays for steroid hormones and sex hormone-binding globulin. Cancer Res 1994;54:5363-7.
40. Breslow NE, Day NE. Statistical methods in cancer research. Volume I-The analysis of case-control studies. IARC Sci Publ 1980;32:5-338.
41. Brinton LA, Barrett RJ, Berman ML, Mortel R, Twiggs LB, Wilbanks GD. Cigarette smoking and the risk of endometrial cancer. Am J Epidemiol 1993;137:281-91.
42. Swanson CA, Wilbanks GD, Twiggs LB, Mortel R, Berman ML, Barrett RJ, et al. Moderate alcohol consumption and the risk of endometrial cancer. Epidemiology 1993;4:530-6.
43. Swanson CA, Potischman N, Barrett RJ, Berman ML, Mortel R, Twiggs LB, et al. Endometrial cancer risk in relation to serum lipids and lipoprotein levels. Cancer Epidemiol Biomarkers Prev 1994;3:575-81.
44. Potischman N, Swanson CA, Brinton LA, McAdams M, Barrett RJ, Berman ML, et al. Dietary associations in a case-control study of endometrial cancer. Cancer Causes Control 1993;4:239-50.
45. Brinton LA, Hoover RN. Epidemiology of gynecologic cancers. In: Hoskins WJ, Perez CA, Young RC, editors. Principles and practice of gynecologic oncology. Philadelphia: Lippincott, 1992:3-26.
46. Shapiro S, Kelly JP, Rosenberg L, Kaufman DW, Helmrich SP, Rosenshein NB, et al. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 1985;313:969-72.
47. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Annu Rev Med 1993;44:121-31.
48. Hautanen A, Adlercreutz H. Altered adrenocorticotropin and Cortisol secretion in abdominal obesity: implications for the insulin resistance syndrome. J Intern Med 1993;234:461-9.
49. Bulun SE, Economos K, Miller D, Simpson ER. CYP19 (aromatase cytochrome P450) gene expression in human malignant endometrial tumors. J Clin Endocrinol Metab 1994;79:1831-4.